Astellas Pharma in deal with Immunomic for JRC2-LAMP-vax, a vaccine for Japanese red cedar pollinosis

3 February 2015

US privately-held clinical-stage biotech firm Immunomic Therapeutics and the US subsidiary of Japanese pharma major Astellas Pharma (TYO: 4503) have entered into an exclusive license agreement for Japan to develop and commercialize the US company’s JRC2-LAMP-vax.

Immunomic’s vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a Phase I trial of JRC2-LAMP-vax in Japan as soon as it is ready.

Deal worth a potential $70 million

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK